Spero Therapeutics (SPRO) Asset Writedowns and Impairment (2023 - 2025)
Spero Therapeutics (SPRO) reported Asset Writedowns and Impairment of $600000.0 for Q3 2025, down 88.69% quarter-over-quarter from $5.3 million in Q3 2023.
Spero Therapeutics (SPRO) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends
Spero Therapeutics has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $600000.0 in Q3 2025.
- For the quarter ending Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $600000.0; the trailing twelve-month figure through Sep 2025 stood at $600000.0 (down 88.69% YoY), and the FY2025 full-year result was $587000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q3 2025 stood at $600000.0, down from $5.3 million in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $5.3 million in Q3 2023, with the low at $600000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 600,000.00 |
| Sep 30, 2025 | 600,000.00 |
| Sep 30, 2023 | 5.31 Mn |
| Sep 30, 2023 | 5.31 Mn |